A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
- Conditions
- COVID-19
- Interventions
- Registration Number
- NCT05047601
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
All participants in the study will receive treatment for COVID-19 as needed, based on their regular doctor's recommendation. Two-thirds of participants will also receive two study medicines (PF-07321332 and ritonavir) by mouth twice a day for either five or ten days. We will compare the experiences of people receiving the study medicines to those of the people who do not. This will help us determine if the study medicines are safe and effective
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2954
- Participants who have a negative screening SARS-CoV-2 rapid antigen test result and who are asymptomatic household contacts with exposure within 96 hours to an individual who is symptomatic and recently tested positive for SARS CoV-2.
- Fertile participants must agree to use a highly effective method of contraception
- History of SARS-CoV-2 infection in the past 6 months
- Experiencing measured fever (documented temperature >38˚C or 100.4˚F) or other signs or symptoms consistent with COVID-19
- Known medical history of active liver disease
- Chronic Kidney Disease or have known moderate to severe renal impairment.
- Known Human Immunodeficiency Virus (HIV) infection with viral load > 400 copies/ml within the last 6 months or taking prohibited medications for HIV treatment
- Suspected or confirmed concurrent active systemic infection
- Active cancer requiring treatment with prohibited medication.
- Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4
- Has received approved, authorized, or investigational anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products within 6 months of screening
- Has received any SARS-CoV-2 vaccine within 6 months prior to screening or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through Day 38.
- Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19
- Known or prior participation in this trial or another trial involving PF-07321332.
- Females who are pregnant or breastfeeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-07321332/ritonavir (5 days) Placebo for PF-07321332 Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10 Placebo Placebo for PF-07321332 Participants will receive placebo every 12 hours from Day 1 through Day 10. Placebo Placebo for Ritonavir Participants will receive placebo every 12 hours from Day 1 through Day 10. PF-07321332/ritonavir (5 days) PF-07321332 Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10 PF-07321332/ritonavir (10-Day) PF-07321332 Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 10. PF-07321332/ritonavir (5 days) Ritonavir Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10 PF-07321332/ritonavir (5 days) Placebo for Ritonavir Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10 PF-07321332/ritonavir (10-Day) Ritonavir Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 10.
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Developed Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 14 Percentage of participants who developed symptomatic Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) or Rapid Antigen Test (RAT) confirmed SARS-Cov-2 infection were reported in this outcome measure. Index case was defined as participants with symptomatic COVID-19.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Asymptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 14 Percentage of participants who had asymptomatic RT-PCR or RAT confirmed SARS-CoV-2 infection through day 14 among participants with negative RT-PCR at baseline were reported in this outcome measure. Index case was defined as participants with symptomatic COVID-19.
Percentage of Participants With Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Positive RT-PCR at Baseline From Day 1 to Day 14 Percentage of participants with a positive RT-PCR result at baseline who had a symptomatic SARS-CoV-2 infection confirmed by RAT or RT-PCR through Day 14 were reported in this outcome measure. Index case was defined as participants with symptomatic COVID-19.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation From start of study intervention (Day 1) up to end of safety follow-up (Day 38) An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening ; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity ; congenital anomaly/birth defect; or that was considered as an important medical event. TEAEs were defined as events that started on or after the study medication start date and time. AEs included both serious and all non-serious adverse events. AEs that led to study discontinuation and AEs that led to discontinuation of study intervention and then continued study were also reported in this outcome measure.
Percentage of Participants Who Developed Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline With Increased Risk of Severe COVID-19 Illness From Day 1 to Day 14 Percentage of participants who had a symptomatic RT-PCR or RAT confirmed SARS-Cov-2 infection were reported in this outcome measure. The risk factors associated with severe covid-19 illness included age greater than or equal to 60 years, body mass index greater than 25, social history of smoking and presence of comorbidities. Index case was defined as participants with symptomatic COVID-19.
Time to RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 14 Number of days between first dose and confirmation of the SARS-CoV-2 infection by RT-PCR or RAT was reported in this outcome measure.
Number of Days of Symptomatic RT-PCR or RAT Confirmed SARS-CoV- 2 Infection Through Day 28: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 28 This outcome measure has been reported in terms of number of participants according to days of symptomatic SARS-CoV-2 infection through Day 28.
Percentage of Participants With Death Event Through Day 38: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 38 Percentage of participants with death (all-cause) event were reported in this outcome measure.
Viral Load in Nasal Samples Over Time: Among Participants With Positive RT-PCR at Baseline From Day 1 to Day 14 Nasal samples were collected to estimate the viral load in terms of logarithm to base 10 (log10) copies per milliliter in participants with positive RT-PCR at baseline and were reported in this outcome measure.
Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28: Among Participants With Negative RT-PCR at Baseline With Increased Risk of Severe COVID-19 Illness From Day 1 to Day 28 The risk factors associated with severe covid-19 illness included age greater than or equal to 60 years, body mass index greater than 25, social history of smoking and presence of comorbidities.
Percentage of Participants With Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative, Positive or Missing RT-PCR at Baseline From Day 1 to Day 14 Percentage of participants with a negative, positive, or missing RT-PCR result at baseline, who had a symptomatic SARS-CoV-2 infection confirmed by RAT or RT-PCR through Day 14 were reported in this outcome measure. Index case was defined as participants with symptomatic COVID-19.
Viral Load in Nasal Samples Over Time: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 14 Nasal samples were collected to estimate the viral load in terms of logarithm to base 10 (log10) copies per milliliter in participants with negative RT-PCR at baseline and were reported in this outcome measure.
Percentage of Participants With no, Mild, Moderate, or Severe Signs and Symptoms Attributed to COVID-19 Through Day 28: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 28 Participants were categorized according to severity of signs and symptoms as no, mild, moderate, severe in this outcome measure. The 12 signs and symptoms included stuffy or runny nose, sore throat, shortness of breath or difficulty breathing, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, nausea, vomiting, diarrhea. Participants recorded their daily severity rating of their symptoms over the past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe.
Plasma Concentration Versus Time Summary of Nirmatrelvir (PF-07321332) Day 1: 1 hour post dose; Day 5: 2 hours pre-dose Number of COVID-19 Related Medical Visits Through Day 28: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 28 In this outcome measure number of COVID-19 related medical visits per day were reported. Number of medical visits per day = number of medical visits/number of days follow up through day 28 visit or the last collection date on or before day 28, if day 28 visit was missing.
Number of Days of Hospitalization and Intensive Care Unit (ICU) Stay: Among Participants With Negative RT-PCR at Baseline From Day 1 to Day 28 This outcome measure has been presented in terms of participants according to number of days of hospitalization and in ICU as 0 days and more than or equal to 1 day.
Trial Locations
- Locations (168)
Accellacare
🇺🇸Ames, Iowa, United States
Clinica de la Costa LTDA.
🇨🇴Barranquilla, Atlantico, Colombia
Medifarma-98 Kft.
🇭🇺Nyiregyhaza, Hungary
City Out-patient clinic #112
🇷🇺Saint-Petersburg, Russian Federation
MERC Welkom
🇿🇦Welkom, FREE State, South Africa
Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4"
🇺🇦Lviv, Ukraine
Ascada Health PC
🇺🇸Fullerton, California, United States
Synergy Healthcare
🇺🇸Bradenton, Florida, United States
Inpatient Research Clinic
🇺🇸Hialeah, Florida, United States
C & R Research Services USA
🇺🇸Houston, Texas, United States
Eastern Research Inc
🇺🇸Hialeah, Florida, United States
Doral Medical Research,LLC
🇺🇸Hialeah, Florida, United States
Christus- Latam Hub Center of Excellence and Innovation Center S.C.
🇲🇽Monterrey, Nuevo LEÓN, Mexico
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),
🇹🇭Pathumwan, Bangkok, Thailand
Faculty of Medicine - Khon Kaen University
🇹🇭Muang, Khon Kaen, Thailand
"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd
🇧🇬Haskovo, Bulgaria
Multiprofile Hospital for Active Treatment - Samokov EOOD
🇧🇬Samokov, Bulgaria
Diagnostic-Consultative Center XXII- Sofia ЕООD
🇧🇬Sofia, Bulgaria
Municipal Non-profit Enterprise "Ivano-Frankivsk Regional Phthisiopulmonology Center of
🇺🇦Ivano-Frankivsk, Ukraine
Municipal Nonprofit Enterprise "City Student Hospital" of Kharkiv City Council
🇺🇦Kharkiv, Ukraine
Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases
🇺🇦Kharkiv, Ukraine
FAICIC Clinical Research
🇲🇽Veracruz, Mexico
Sociedad de Metabolismo y Corazon S.C.
🇲🇽Veracruz, Mexico
LLC Strategic Medical Systems
🇷🇺Saint Petersburg, Russian Federation
City Polyclinic No. 109
🇷🇺Saint-Petersburg, Russian Federation
Smolensk State Medical University
🇷🇺Smolensk, Russian Federation
LLC Family clinic
🇷🇺Yekaterinburg, Russian Federation
King Chulalongkorn Memorial Hospital
🇹🇭Bangkok, Thailand
Tropical Medicine Hospital
🇹🇭Bangkok, Thailand
InfectoLab Consultorios de Especialidad en Infectologia
🇲🇽Tijuana, BAJA California, Mexico
Hospital Miri
🇲🇾Miri, Sarawak, Malaysia
Eukarya Pharmasite S.C.
🇲🇽Monterrey, Nuevo LEON, Mexico
City Polyclinic #44
🇷🇺Saint Petersburg, Russian Federation
Communal non-profit enterprise "City Clinical Hospital #16" of Dnipro City Council
🇺🇦Dnipro, Ukraine
NHC Thohoyandou CRS
🇿🇦Thohoyandou, Limpopo, South Africa
Saint-Petersburg State Budgetary Healthcare Institution "City Pokrovskaya hospital"
🇷🇺Saint-Petersburg, Russian Federation
City Out-patient clinic #4
🇷🇺Saint-Petersburg, Russian Federation
Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional
🇺🇦Poltava, Ukraine
Communal Enterprise "Hospital #1" of Zhytomyr City Council
🇺🇦Zhytomyr, Ukraine
Optimus Medical Group
🇺🇸San Francisco, California, United States
Angels Clinical Research Institute
🇺🇸Miami, Florida, United States
LCC Medical Research Institute, LLC
🇺🇸Miami, Florida, United States
Premium Medical Research Corp
🇺🇸Miami, Florida, United States
Global Health Clinical Trials Corp
🇺🇸Miami, Florida, United States
South Florida Research Center, Inc.
🇺🇸Miami, Florida, United States
University of Miami Health System
🇺🇸Miami, Florida, United States
I.V.A.M. Clinical & Investigational Center, LLC
🇺🇸Miami, Florida, United States
C'A Research
🇺🇸Miami, Florida, United States
ProLive Medical Research, Corp.
🇺🇸Miami, Florida, United States
Clinical Site Partners, Inc dba CSP Miami
🇺🇸Miami, Florida, United States
Kendall South Medical Center, Inc.
🇺🇸Miami, Florida, United States
Coral Research Clinic Corp
🇺🇸Miami, Florida, United States
Santos Research Center, CORP
🇺🇸Tampa, Florida, United States
Quality Clinical Research Inc
🇺🇸Omaha, Nebraska, United States
Walmart
🇺🇸Las Vegas, Nevada, United States
Excel Clinical research
🇺🇸Las Vegas, Nevada, United States
Walgreens
🇺🇸Las Vegas, Nevada, United States
Sun Research Institute
🇺🇸San Antonio, Texas, United States
The Institute for Liver Health dba Arizona Clinical Trials
🇺🇸Tucson, Arizona, United States
Cahaba Research Inc
🇺🇸Pelham, Alabama, United States
MOORE Clinical Research, Inc.
🇺🇸Brandon, Florida, United States
Advance Clinical Research Group
🇺🇸Cutler Bay, Florida, United States
Herco Medical and Research Center Inc
🇺🇸Coral Gables, Florida, United States
TrueBlue Clinical Research
🇺🇸Brandon, Florida, United States
Beautiful Minds Clinical Research Center
🇺🇸Cutler Bay, Florida, United States
Qway Research
🇺🇸Hialeah, Florida, United States
ASCLEPES Research Centers
🇺🇸Spring Hill, Florida, United States
Pro-Care Research Center, Corp.
🇺🇸Miami Gardens, Florida, United States
Savin Medical Group, LLC
🇺🇸Miami Lakes, Florida, United States
Medical Research of Westchester Inc
🇺🇸Miami, Florida, United States
Entrust Clinical Research
🇺🇸Miami, Florida, United States
Reed Medical Research
🇺🇸Miami, Florida, United States
GCP, Global Clinical Professionals
🇺🇸Saint Petersburg, Florida, United States
NAPA Research LLC
🇺🇸Pompano Beach, Florida, United States
CDC Research Institute, LLC
🇺🇸Port Saint Lucie, Florida, United States
USPA Advance Concept Medical Research Group LLC
🇺🇸South Miami, Florida, United States
Sunrise Research Institute
🇺🇸Sunrise, Florida, United States
Research by Design, LLC
🇺🇸Chicago, Illinois, United States
McFarland Clinic, PC
🇺🇸Ames, Iowa, United States
Meridian Clinical Research, LLC
🇺🇸Grand Island, Nebraska, United States
Quality Clinical Research
🇺🇸Omaha, Nebraska, United States
NYC Health + Hospitals / Harlem
🇺🇸New York, New York, United States
Monroe Biomedical Research
🇺🇸Monroe, North Carolina, United States
PharmaTex Research, LLC
🇺🇸Amarillo, Texas, United States
Innovo Research: Wilmington Health
🇺🇸Wilmington, North Carolina, United States
South Texas Clinical Research
🇺🇸Corpus Christi, Texas, United States
Conroe Willis Medical Research
🇺🇸Conroe, Texas, United States
SingnatureCare Emergency Center
🇺🇸Houston, Texas, United States
Trio Clinical Trials, LLC
🇺🇸Houston, Texas, United States
Epic Medical Research
🇺🇸Red Oak, Texas, United States
SMS Clinical Research, LLC
🇺🇸Mesquite, Texas, United States
Pesquisare Saude S/S Ltda
🇧🇷Santo André, SP, Brazil
Tranquility Research
🇺🇸Webster, Texas, United States
Instituto de Investigaciones Clinicas Zarate
🇦🇷Zarate, Buenos Aires, Argentina
Conjunto Hospitalar do Mandaqui
🇧🇷São Paulo, Brazil
Instituto Médico de la Fundación Estudios Clínicos (Fundación Estudios Clínicos)
🇦🇷Rosario, Santa FE, Argentina
MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD
🇧🇬Kozloduy, Bulgaria
Diagnostic-Consultative Center I Lom EOOD
🇧🇬Lom, Bulgaria
Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD
🇧🇬Lom, Bulgaria
DCC Sveti Georgi EOOD
🇧🇬Plovdiv, Bulgaria
MHAT "St. Panteleimon "- Plovdiv
🇧🇬Plovdiv, Bulgaria
Medical centre Leo Clinic EOOD
🇧🇬Lovech, Bulgaria
MHAT Heart and Brain EAD
🇧🇬Pleven, Bulgaria
UMHAT Medica Ruse OOD
🇧🇬Ruse, Bulgaria
Multiprofile hospital for active treatment - Sliven to Military Medical Academy
🇧🇬Sliven, Bulgaria
UMHATEM N. I. Pirogov EAD
🇧🇬Sofia, Bulgaria
Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD
🇧🇬Stara Zagora, Bulgaria
Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD
🇧🇬Vratsa, Bulgaria
Medical center Leo Clinic EOOD
🇧🇬Varna, Bulgaria
MOBAL "D-r Stefan Cherkezov" AD
🇧🇬Veliko Tarnovo, Bulgaria
Doktor Brno s.r.o.
🇨🇿Brno, Czechia
Cireem Sas
🇨🇴Bogota, Cundinamarca, Colombia
Caimed S.A.S.
🇨🇴Yopal, Casanare, Colombia
Nemocnice Slany
🇨🇿Slany, Czechia
Zdraví-Fit, s.r.o.
🇨🇿Protivín, Czechia
Rakuwakai Otowa Hospital
🇯🇵Kyoto-shi, Kyoto, Japan
International University of Health and Welfare Narita Hospital
🇯🇵Narita, Chiba, Japan
Rinku General Medical Center
🇯🇵Izumisano, Osaka, Japan
Denenchofu Family Clinic
🇯🇵Ota, Tokyo, Japan
Sekino Hospital
🇯🇵Toshimaku, Tokyo, Japan
Instituto Jalisciense de Metabolismo, S.C.
🇲🇽Guadalajara, Jalisco, Mexico
Clinical Research Institute Saltillo S.A. de C.V.
🇲🇽Saltillo, Coahuila, Mexico
Instituto de Investigaciones Clinicas para la Salud A.C.
🇲🇽Durango, Mexico
Kirovsk Interdistrict Hospital
🇷🇺Kirovsk, Leningrad Region, Russian Federation
Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska
🇵🇱Wroclaw, Poland
LLC Trekhgorka Medicine
🇷🇺Odintsovo, Moscow Region, Russian Federation
Barnaul City Hospital Number 5
🇷🇺Barnaul, Russian Federation
Clinica UZI 4D
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
Korolev Medicine
🇷🇺Korolev, Russian Federation
KDC "Evromedservis", OJSC
🇷🇺Moscow, Russian Federation
LLC Kurator
🇷🇺Saint-Petersburg, Russian Federation
"Research Center Eco-safety" LLC
🇷🇺Saint-Petersburg, Russian Federation
Worthwhile Clinical Trials
🇿🇦Benoni, Gauteng, South Africa
LCS Clinical Research
🇿🇦Johannesburg, Gauteng, South Africa
Global Clinical Trials
🇿🇦Pretoria, Gauteng, South Africa
About Allergy (PTY) Ltd
🇿🇦Pretoria, Gauteng, South Africa
Peermed CTC (Pty) Ltd T/A MERC Kempton
🇿🇦Kempton Park, Gauteng, South Africa
Clinical Trial Systems (Pty) Ltd
🇿🇦Pretoria, Gauteng, South Africa
Into Research
🇿🇦Pretoria, Gauteng, South Africa
Botho Ke Bontle Health Services
🇿🇦Pretoria, Gauteng, South Africa
Sandton Medical Clinic
🇿🇦Sandton, Gauteng, South Africa
Synapta Clinical Research Center
🇿🇦Durban, Kwazulu Natal, South Africa
Dr PJ Sebastian Clinical Research Centre
🇿🇦Durban, Kwa-zulu Natal, South Africa
Ahmed Al-Kadi Private Hospital
🇿🇦Mayville, Durban, Kwazulu-natal, South Africa
Limpopo Clinical Research Initiative
🇿🇦Thabazimbi, Limpopo, South Africa
Madibeng Centre for Research
🇿🇦Brits, North WEST, South Africa
MERC Middelburg
🇿🇦Middelburg, Mpumalanga, South Africa
Complexo Hospitalario Universitario da Coruna
🇪🇸A Coruña, Spain
FCRN Clinical Trial Centre
🇿🇦Vereeniging, South Africa
Faculty of Tropical Medicine, Mahidol University
🇹🇭Bangkok, Thailand
Istanbul University Istanbul Medical Faculty
🇹🇷Fatih / Istanbul, Turkey
Ankara University Medical Faculty, Ibni-Sina Hospital
🇹🇷Ankara, Turkey
Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi
🇹🇷Gaziantep, Turkey
Acibadem University Atakent Hospital
🇹🇷Istanbul, Turkey
Mersin University Medical Faculty
🇹🇷Mersin, Turkey
Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital
🇹🇷Izmir, Turkey
Karadeniz Teknik Universitesi Farabi Hastanesi
🇹🇷Trabzon, Turkey
Communal non-commercial Enterprise "City Central Clinical Hospital" of Chernivtsi City Council
🇺🇦Chernivtsi, Ukraine
Regional Communal Nonprofit Institution "Chernivtsi Regional Clinical Hospital"
🇺🇦Chernivtsi, Ukraine
Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council"
🇺🇦Ivano-Frankivsk, Ukraine
Municipal Nonprofit Enterprise "City Clinic Hospital # 13" of Kharkiv City Council
🇺🇦Kharkiv, Ukraine
Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company
🇺🇦Kyiv, Ukraine
Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council
🇺🇦Tarasove Village, Ukraine
Municipal NonProfit Enterprise of the Lviv Regional Council Lviv Regional Information and Analytical
🇺🇦Lviv, Ukraine
Omega Research Orlando
🇺🇸Orlando, Florida, United States
EME RED Hospitalaria
🇲🇽Mérida, Yucatán, Mexico
Southern Clinical Research Associates. LLC
🇺🇸Metairie, Louisiana, United States
Unlimited Medical Research Group, LLC
🇺🇸Hialeah Gardens, Florida, United States